Evidence map›Paper›PMID 33536294›Full record

ArticleJournal of clinical microbiology2021

Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania.

Peter M Mbelele, Emmanuel A Mpolya, Elingarami Sauli, Bariki Mtafya, Nyanda E Ntinginya, Kennedy K Addo, Katharina Kreppel, Sayoki Mfinanga, Patrick P J Phillips, Stephen H Gillespie and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022
    Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 4 countries.

Peter M MbeleleKibong'oto Infectious Diseases Hospital (KIDH), Siha, Kilimanjaro, Tanzania mbelelepeter@yahoo.com.ORCID 0000-0002-2693-187X
Emmanuel A MpolyaDepartment of Global Health and Biomedical Sciences, School of Life Sciences and Bioengineering, Nelson Mandela African Institution of Science and Technology (NM-AIST), Arusha, Tanzania.
Elingarami SauliDepartment of Global Health and Biomedical Sciences, School of Life Sciences and Bioengineering, Nelson Mandela African Institution of Science and Technology (NM-AIST), Arusha, Tanzania.
Bariki MtafyaNational Institute for Medical Research, Mbeya Medical Research Centre, Mbeya, Tanzania.
Nyanda E NtinginyaNational Institute for Medical Research, Mbeya Medical Research Centre, Mbeya, Tanzania.
Kennedy K AddoDepartment of Bacteriology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Katharina KreppelDepartment of Global Health and Biomedical Sciences, School of Life Sciences and Bioengineering, Nelson Mandela African Institution of Science and Technology (NM-AIST), Arusha, Tanzania.
Sayoki MfinangaNational Institute for Medical Research, Muhimbili Centre, Dar Es Salaam, Tanzania.
Patrick P J PhillipsUCSF Center for Tuberculosis, University of San Francisco, San Francisco, California, USA.
Stephen H GillespieSchool of Medicine, University of St Andrews, St. Andrews, Scotland, United Kingdom.
Scott K HeysellDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA.
Wilber SabiitiSchool of Medicine, University of St Andrews, St. Andrews, Scotland, United Kingdom.
Stellah G MpagamaKibong'oto Infectious Diseases Hospital (KIDH), Siha, Kilimanjaro, Tanzania.
National Institute for Medical Research · TZNelson Mandela African Institution of Science and Technology · TZKilimanjaro Christian Medical Centre · TZUniversity of St Andrews · GBUniversity of Ghana · GHUniversity of San Francisco · USUniversity of Virginia · US

Funding

Diagnostics and Pharmacotherapy for Severe Forms of TBU01AI115594 · NIAID · UNIVERSITY OF VIRGINIA · PI HEYSELL, SCOTT K, HOUPT, ERIC R · 2015 to 2019
$3.0M
EPA EP-C-15-008NIAID NIH HHS U01 AI115594Wellcome TrustWellcome Trust 107753/A/15/Z
6 · The paper itself

Abstract

Rifampin or multidrug-resistant tuberculosis (RR/MDR-TB) treatment has largely transitioned to regimens free of the injectable aminoglycoside component, despite the drug class' purported bactericidal activity early in treatment. We tested whether

Indexed as

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsBacterial LoadDiarylquinolinesHumansRNA, Ribosomal, 16STanzaniaAntitubercular AgentsDiarylquinolinesRNA, Ribosomal, 16Sall-oral bedaquiline regimeninjectable aminoglycoside regimenKibong'otoMDR-TB treatment regimensmolecular bacterial load assaymultidrug-resistant TBmycobactericidal effectsMycobacterium tuberculosisTanzania

Identifiers

PMID33536294
PMCPMC8092737
OpenAlexW3129178808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.